QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.107.121178v1 322/1/141    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Vliet, E. A. Articles by Gorter, J. A. Search for Related Content PubMed PubMed Citation Articles by van Vliet, E. A. Articles by Gorter, J. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Epilepsy Hazardous Substances DB PHENYTOIN SODIUM

NEUROPHARMACOLOGY

Region-Specific Overexpression of P-glycoprotein at the Blood-Brain Barrier Affects Brain Uptake of Phenytoin in Epileptic Rats

Epilepsy Institute of The Netherlands, Heemstede, The Netherlands (E.A.v.V., P.M.E., R.A.V., J.A.G.); Center for Neuroscience, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands (E.A.v.V., R.v.S., W.J.W., J.A.G.); Leiden/Amsterdam Center for Drug Research, Division of Pharmacology, Leiden, The Netherlands (R.A.V.).; and Department of (Neuro) Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (S.R., E.A.)

Recent studies have suggested that overexpression of the multidrug transporter P-glycoprotein (P-gp) in the hippocampal region leads to decreased levels of antiepileptic drugs and contributes to pharmacoresistance that occurs in a subset of epileptic patients. Whether P-gp expression and function is affected in other brain regions and in organs that are involved in drug metabolism is less studied. Therefore, we investigated P-gp expression in different brain regions and liver of chronic epileptic rats, several months after electrically induced status epilepticus (SE), using Western blot analysis. P-gp function was determined by measuring phenytoin (PHT) levels in these brain regions using high-performance liquid chromatography, in the absence and presence of a P-gp-specific inhibitor, tariquidar (TQD). In addition, the pharmacokinetic profile of PHT was determined. PHT concentration was reduced by 20 to 30% in brain regions that had P-gp overexpression (temporal hippocampus and parahippocampal cortex) and not in brain regions in which P-gp expression was not changed after SE. Inhibition of P-gp by TQD significantly increased the PHT concentration, specifically in regions that showed P-gp overexpression. Despite increased P-gp expression in the liver of epileptic rats, pharmacokinetic analysis showed no significant change of PHT clearance in control versus epileptic rats. These findings show that overexpression of P-gp at the blood-brain barrier of specific limbic brain regions causes a decrease of local PHT levels in the rat brain.

Address correspondence to: Dr. Jan A. Gorter, Center for Neuroscience, Swammerdam Institute for Life Sciences, Kruislaan 320, 1098 SM, Amsterdam, The Netherlands. E-mail: gorter{at}science.uva.nl

This article has been cited by other articles:

				A. Pekcec, B. Unkruer, J. Schlichtiger, J. Soerensen, A. M. S. Hartz, B. Bauer, E. A. van Vliet, J. A. Gorter, and H. Potschka Targeting Prostaglandin E2 EP1 Receptors Prevents Seizure-Associated P-glycoprotein Up-Regulation J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 939 - 947. [Abstract] [Full Text] [PDF]